{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-25-000096","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2025-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.967416+00:00","generated_at":"2026-05-19T23:55:23.596182+00:00","sec_items":["1.01","2.03","3.02","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Elicio Therapeutics secures $10M senior secured note from board-affiliated investor","bullets":["Issued $10M promissory note to GKCC (controlled by board member); interest rate up to 12.5%.","Warrant to purchase 103,225 shares at $7.75 issued; immediately exercisable, 5-year term.","Proceeds plus current cash expected to fund operations into Q1 2026.","AMPLIFY-7P Phase 2 interim analysis for ELI-002 in PDAC anticipated in Q3 2025.","Note matures June 3, 2028; 24-month interest-only period with lump-sum interest payment."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-25-000096","json":"https://secwatch.observer/filing/0001601485-25-000096.json","markdown":"https://secwatch.observer/filing/0001601485-25-000096.md","text":"https://secwatch.observer/filing/0001601485-25-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000096/0001601485-25-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000096/angn-20250604.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T23:55:23.596182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e3eb928675f390370eba30c218dcfc196e6f4b83","claim":"Elicio Therapeutics, Inc. incurred senior notes of $10.0 million with GKCC, LLC at Prime Rate plus 5.00%, maximum 12.5% per annum maturing June 3, 2028.","evidence_excerpt":"On June 3, 2025, Elicio Therapeutics, Inc. (the “Company”) entered into a note purchase agreement (the “Note Purchase Agreement”) pursuant to which the Company issued a Senior Secured Promissory Note due June 3, 2028 (the “Promissory Note”) in the principal amount of $10.0 million (the “Note Financing”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000096/0001601485-25-000096-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"$10.0 million"},{"label":"Counterparty","value":"GKCC, LLC"},{"label":"Rate","value":"Prime Rate plus 5.00%, maximum 12.5% per annum"},{"label":"Maturity","value":"June 3, 2028"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}